Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study

[1]  M. Congreve,et al.  First‐in‐man study to investigate safety, pharmacokinetics and exploratory pharmacodynamics of HTL0018318, a novel M1‐receptor partial agonist for the treatment of dementias , 2020, British journal of clinical pharmacology.

[2]  D. Erskine,et al.  Cholinergic muscarinic M1 and M4 receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. , 2019, Drug discovery today.

[3]  W. Dale Stevens,et al.  Meta-analyses of the n-back working memory task: fMRI evidence of age-related changes in prefrontal cortex involvement across the adult lifespan , 2019, NeuroImage.

[4]  C. Lustig,et al.  Forebrain Cholinergic Signaling: Wired and Phasic, Not Tonic, and Causing Behavior , 2019, The Journal of Neuroscience.

[5]  J. V. van Gerven,et al.  Reversal of mecamylamine‐induced effects in healthy subjects by nicotine receptor agonists: Cognitive and (electro) physiological responses , 2018, British journal of clinical pharmacology.

[6]  J. Cummings,et al.  Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease , 2018, Alzheimer's & dementia.

[7]  J. Wess,et al.  Muscarinic acetylcholine receptors act in synergy to facilitate learning and memory , 2016, Learning & memory.

[8]  A. Maelicke,et al.  First in human study with a prodrug of galantamine: Improved benefit-risk ratio? , 2016, Alzheimer's & dementia.

[9]  J. Uslaner,et al.  The M1 Muscarinic Positive Allosteric Modulator PQCA Improves Performance on Translatable Tests of Memory and Attention in Rhesus Monkeys , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[10]  Christian C. Felder,et al.  Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus , 2015, Cerebral cortex.

[11]  S. Salpeter,et al.  A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence , 2015, Drugs & Aging.

[12]  Anil Kumar,et al.  A review on Alzheimer’s disease pathophysiology and its management: an update , 2015, Pharmacological reports : PR.

[13]  P. Rossini,et al.  Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients , 2013, Clinical Neurophysiology.

[14]  E. Bullmore,et al.  The potent M1 receptor allosteric agonist GSK1034702 improves episodic memory in humans in the nicotine abstinence model of cognitive dysfunction. , 2013, The international journal of neuropsychopharmacology.

[15]  S. Hitchcock,et al.  Pharmacological Characterization of LY593093, an M1 Muscarinic Acetylcholine Receptor-Selective Partial Orthosteric Agonist , 2011, Journal of Pharmacology and Experimental Therapeutics.

[16]  M. Sabbagh,et al.  Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer’s disease , 2011, Acta Neuropathologica.

[17]  Lesley K. Fellows,et al.  Lesion Evidence That Two Distinct Regions within Prefrontal Cortex are Critical for n-Back Performance in Humans , 2009, Journal of Cognitive Neuroscience.

[18]  F. LaFerla,et al.  M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.

[19]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[20]  T. Finucane.  Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. , 2004, Annals of internal medicine.

[21]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[22]  J. Karlawish,et al.  Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies , 2003, Annals of Internal Medicine.

[23]  F Barkhof,et al.  Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[24]  E. Feigl,et al.  Altered cardiovascular responses in mice lacking the M(1) muscarinic acetylcholine receptor. , 2002, The Journal of pharmacology and experimental therapeutics.

[25]  M. Wienrich,et al.  Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. , 2001, Life sciences.

[26]  K. White,et al.  Facilitation of Memory Performance by a Novel Muscarinic Agonist in Young and Old Rats , 1999, Pharmacology Biochemistry and Behavior.

[27]  W W Offen,et al.  Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB). , 1998, Alzheimer disease and associated disorders.

[28]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[29]  N. Cutler,et al.  The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's Disease , 1995, Journal of clinical pharmacology.

[30]  E. Perry,et al.  Acetylcholine and Hallucinations - Disease-Related Compared to Drug-Induced Alterations in Human Consciousness , 1995, Brain and Cognition.

[31]  K. Gough,et al.  Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party , 1995 .

[32]  D. Mash,et al.  Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease , 1995, Journal of neurochemistry.

[33]  R. Ihl,et al.  Event-related potentials and psychopharmacology. Cholinergic modulation of P300. , 1994, Pharmacopsychiatry.

[34]  J. Miller,et al.  Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. , 1993, Archives of neurology.

[35]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[36]  R. Coppola,et al.  The distribution of cerebral muscarinic acetylcholine receptors in vivo in patients with dementia. A controlled study with 123IQNB and single photon emission computed tomography. , 1991, Archives of neurology.

[37]  G. K. Wilcock,et al.  Plaques, tangles and dementia A quantitative study , 1982, Journal of the Neurological Sciences.

[38]  Brenda Milner,et al.  Visually-guided maze learning in man: effects of bilateral hippocampal, bilateral frontal, and unilateral cerebral lesions , 1965 .

[39]  Jin-Tai Yu,et al.  Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. , 2014, Journal of Alzheimer's disease : JAD.

[40]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[42]  A. Levey,et al.  Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. , 1993, Life sciences.